Investigation of Anti–Middle East Respiratory Syndrome Antibodies in Blood Donors and Slaughterhouse Workers in Jeddah and Makkah, Saudi Arabia, Fall 2012

Asad S. Aburizaiza,1 Frank M. Mattes,2,3 Esam I. Azhar,2,3 Ahmed M. Hassan,2 Ziad A. Memish,4 Doreen Muth,5 Benjamin Meyer,5 Erik Lattwein,7 Marcel A. Müller,5 and Christian Drosten6

1Environmental Science Department, Faculty of Metrology, Environmental Science and Arid Land Agriculture, 2Special Infectious Agents Unit, King Fahd Medical Research Center, and 3Medical Laboratory Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, and 4Ministry of Health, Riyadh, Saudi Arabia; 5German International Cooperation, Eschborn; 6Institute of Virology, University of Bonn Medical Center, Bonn, and 7EUROIMMUN AG, Lübeck, Germany

DOI: 10.1093/infdis/jit589

(See the editorial commentary by Hui and Zumla on pages 173–6, and the major article by Yao et al on pages 236–42.)

Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel, potentially zoonotic human coronavirus (HCoV). We investigated MERS-CoV antibodies using a staged approach involving an immunofluorescence assay (IFA), a differential recombinant IFA, and a plaque-reduction serum neutralization assay. In 130 blood donors sampled during 2012 in Jeddah and 226 slaughterhouse workers sampled in October 2012 in Jeddah and Makkah, Saudi Arabia, 8 reactive sera were seen in IFA but were resolved to be specific for established HCoVs by discriminative testing. There is no evidence that MERS-CoV circulated widely in the study region in fall 2012, matching an apparent absence of exported disease during the 2012 Hajj.

Keywords. MERS-CoV; serology; population immunity.

Received 19 July 2013; accepted 26 September 2013; electronically published 11 November 2013.

* A. S. A. and F. M. M. contributed equally to this study.

Presented in part: World Health Organization scientific consultation meeting on MERS-CoV research, Cairo, Egypt, 19 June 2013.

Correspondence: Christian Drosten, MD, Institute of Virology, University of Bonn Medical Center, Sigmund Freud Str 25, 53105 Bonn, Germany (drosten@virology-bonn.de).

The Journal of Infectious Diseases 2014;209:243–6

© The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

DOt: 10.1093/infdis/jit589

METHODS

IFA using full MERS-CoV was performed with a commercially available test kit (Anti-MERS-CoV IIFT, EUROIMMUN AG,
Lübeck, Germany) exactly as described elsewhere [8]. Discriminatory recombinant IFA followed a described protocol [8] and was extended for the purpose of this study to include full spike proteins (the complete S open reading frame) of HCoV 229E, NL63, OC43, HKU1, and MERS-CoV expressed from pCG1 eukaryotic expression vectors.

For serum neutralization tests, Vero B4 cells were grown to subconfluence in 24-well plates. Preincubation reactions contained 25 plaque-forming units of MERS-CoV (EMC strain) in 100 µL of medium, mixed 1:1 with patients’ serum specimens prediluted in medium. The starting dilution was 1:10. After 1 hour of incubation at 37°C, each well was infected for 1 hour at 37°C, using the total 200-µL preincubation reaction. Supernatants were removed and overlaid with Avicell resin exactly as described by Herzog et al [10]. Assays were terminated and stained by immersion in formaldehyde/crystal violet solution after 3 days, thereby inactivating the test virus [10]. Neutralization titers were defined as the serum dilution reducing the number of plaques in 4 parallel wells in summary by >90%.

All enrolled slaughterhouse workers gave blood voluntarily and provided written informed consent to have their blood samples tested for MERS-CoV antibodies.

RESULTS

For a first and orienting assessment of antibodies in the local population, an anonymized panel of serum specimens from 130 healthy blood donors was assembled. These individuals had been submitted for blood donor eligibility screening at King Abdulaziz University Hospital, Jeddah, between January and December 2012. Samples were tested at a predilution of 1:40 by IFA as described elsewhere [8], yielding no specific fluorescence signal in any case. Of note, in a previous study, IFAs of serum specimens from blood donors did not cross-react at this dilution [8].

Because of reports on potential exposures with livestock animals in MERS cases, workers from 2 slaughterhouses in Jeddah and 3 slaughterhouses in Makkah were investigated in October 2012. Slaughtered animals included cattle, camels, and sheep. The workers were aged 16–61 years, had worked in slaughterhouses for intervals ranging from 2 months to 36 years, and were from various countries, including Bangladesh (n = 74), Burkina Faso (n = 1), Egypt (n = 24), India (n = 9), Mali (n = 12), Niger (n = 10), Pakistan (n = 21), Saudi Arabia (n = 9), Sudan (n = 10), and Yemen (n = 58). Workers had lived in Saudi Arabia for durations ranging from 3 months to 36 years. Upon initial screening using IFA slides containing cells infected with full MERS-CoV, 8 of 226 serum specimens yielded specific IFA patterns. There were no apparent differences in detection rates between individual study sites (Table 1).

All 8 samples were further investigated using discriminative recombinant IFA. As summarized in Table 2, all 8 specimens showed dominant titers against recombinant spike proteins of HCoVs other than MERS-CoV. Only 2 of the 8 specimens reacted with MERS-CoV. In contrast, specimens from 2 subjects with laboratory-confirmed MERS showed clear reactivity with recombinant MERS-CoV spike proteins. These patients’ specimens had concomitant reactivity against spike proteins from other HCoVs, as well, which was to be expected because of the recency of MERS-CoV infection in these patients, involving low-avidity antibodies (both patients were anti-MERS-CoV immunoglobulin M positive) [3].

All 8 samples were additionally tested for the presence of neutralizing antibodies. To detect serum neutralization, serum specimens were incubated with 25 plaque-forming units of MERS-CoV strain EMC/2012 for 1 hour before they were adsorbed onto Vero cells for another 1 hour. Cells were then overlaid with Avicell resin and incubated at 37°C for 3 days. Serum dilutions affecting >90% reduction of the cumulative number of resulting plaques in 4 replicate assays were recorded as serum neutralization titers (NT90). Because serum dilutions of 1:5 appeared as NT90 in a small fraction of blood samples from healthy German adults who did not have anti–MERS-CoV antibodies, a dilution of 1:10 was chosen as the titration limit (ie, starting dilution) in neutralization assays. As summarized in Table 2, none of these 8 specimens had serum neutralization titers >2-fold the titration limit, whereas serum specimens from 2 patients with laboratory-confirmed MERS-CoV infection had clear neutralization titers.

DISCUSSION

Our investigation yields 2 major conclusions. First, we demonstrated that immunofluorescence analysis using virus-infected
cells will, if performed alone rather than as part of a set of analyses, return false-positive MERS-CoV antibody results for a fraction of patients. Of note, IFA is considered a highly robust assay because of the possibility to inspect the specific fluorescence staining patterns in virus-infected cells, providing an additional diagnostic criterion that is not available in other serology formats, such as enzyme immunoassays (EIA). The same propensity for false-positive results is therefore to be expected with EIA that use full virus as the test antigen. Future studies should take this into account to avoid any false-positive end points. Exact delineation of specific antigenic epitopes within the MERS-CoV spike protein, which could then be used as a recombinant antigen in EIA, could be useful in the development of a more-reliable protocol for serological detection of MERS-CoV.

Second, we found no significant rates of antibodies against MERS-CoV in individuals living in the Jeddah and Makkah regions. However, the number of samples analyzed in this preliminary study is limited, making it impossible from a statistical perspective to exclude the presence of antibodies in the population. Furthermore, although we know that IFA will readily detect antibodies in clinically severe cases of MERS-CoV infection, it is conceivable that lower levels of antibodies could exist in mild or asymptomatic cases. Nevertheless, we believe that our data suggest that long-term circulation of MERS-CoV at the population level is not occurring in the area from which our target population was sampled. The population should therefore be largely susceptible to MERS-CoV infection. Of note, the investigated geographical area overlaps with the destination for the Hajj and the Umrah, where millions of pilgrims gather each year and respiratory viruses are known to be acquired and transmitted at high rates [11, 12]. The absence of antibodies in our study is consistent with the absence of reports of any MERS-CoV infection in pilgrims returning from the Hajj in 2012 [11, 13].

Notes

Financial support. This work was supported by the Municipality of the Holy City of Makkah, Saudi Arabia; the European Management Platform for Emerging and Re-emerging Infectious Disease Entities (contract 223498, for work in Germany); the German Center for Infection Research (infrastructure support to C. D.); and the German Ministry for Research and Education and the German Research Council (grants 01KIO701 and DR 772/3-1 for virological analyses).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of middle east respiratory syndrome coronavirus infections. N Engl J Med 2013; 368:2487–94.
2. Cauchemez S, Epperson S, Biggerstaff M, Swerdlow D, Finelli L, Ferguson NM. Using routine surveillance data to estimate the epidemic potential of emerging zoonoses: application to the emergence of US swine origin influenza A H3N2v virus. PLoS Med 2013; 10:e1001399.
3. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013; 13:745–51.

4. Reusken CB, Haagmans BL, Muller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013; pii: S1473-3099(13)70164-6.

5. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013; 67:130–40.

6. Buchholz U, Muller MA, Nitsche A, et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill 2013; 18. pii: 20406.

7. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV); announcement of the coronavirus study group. J Virol 2013; 87:7790–2.

8. Corman V, Muller M, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012; 17. pii: 20334.

9. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814–20.

10. Herzog P, Drosten C, Muller MA. Plaque assay for human coronavirus NL63 using human colon carcinoma cells. Virol J 2008; 5:138.

11. Al-Tawfiq JA, Memish ZA. The Hajj: updated health hazards and current recommendations for 2012. Euro Surveill 2012; 17:20295.

12. Benkouiten S, Charrel R, Belhouchat K, et al. Circulation of respiratory viruses among pilgrims during the 2012 Hajj pilgrimage. Clin Infect Dis 2013; 57:992–1000.

13. Gautret P, Charrel R, Belhouchat K, et al. Lack of nasal carriage of novel coronavirus (HCoV-EMC) in French Hajj pilgrims returning from the Hajj 2012, despite a high rate of respiratory symptoms. Clin Microbiol Infect 2013; 19:E315–7.